Mechanisms and consequences of 3'UTR isoform diversity in erythropoiesis
Project Number5F31HL162546-02
Contact PI/Project LeaderGAZZARA, MATTHEW ROBERT
Awardee OrganizationUNIVERSITY OF PENNSYLVANIA
Description
Abstract Text
Project Summary
The 3’ untranslated region (3’UTR) of mature messenger RNAs (mRNAs) is the sequence between the stop
codon of the coding sequence and poly(A) tail. Importantly, the location where the 3’end processing machinery
adds the poly(A) tail to the pre-mRNA is not invariant, but changes in a controlled manner to generate 3’UTR
isoform diversity between mRNAs of the same gene. This process is known as alternative polyadenylation
(APA). Although the 3’UTR isoforms generated through APA do not alter the amino acid sequence of the
protein, they influence expression by adding or removing binding sites for microRNAs and RNA binding
proteins (RBPs) that influence mRNA export, stability, localization, and translation efficiency. Targeted 3’end
sequencing techniques have shown APA to be widespread and regulated between tissues and in specific
disease contexts. Despite the prevalence of APA , a regulatory understanding of which RBPs drive this process
remains limited. Cells of specific hematopoietic lineages were found to display pervasive APA, but no
comprehensive map of APA in the erythroid lineage exists. Other RNA processing events, like alternative
splicing and translational control, are known to be important for erythropoiesis and dysregulated in certain
anemias and thalassemias, suggesting that APA altering the length/identity of 3’UTRs may also influence
erythroid biology in health and disease. This project seeks to fill this knowledge gap by comprehensively
identifying and quantifying APA during erythropoiesis using targeted 3’end sequencing on RNA collected from
erythroid cells throughout differentiation. Preliminary data suggests several genes essential for erythropoiesis,
like transcription factors TAL1 (SCL) and TCF3 (E2A), undergo APA shifts during this process. The functional
impact of different 3’UTR isoform choices will be assessed by monitoring impact on mRNA and protein levels
(luciferase assays) and differentiation efficacy (CRISPR deletions to force isoform expression). Finally, this
project will identify key regulators of the APA shifts across erythropoiesis by analyzing a large compendium of
RBP knockdown, mutation, and knockout experiments from K562 erythroleukemia cells followed by
experimental validation. Preliminary data suggests splicing factors commonly mutated in myelodysplastic
syndromes (MDS, a condition characterized, in part by ineffective erythropoiesis) like SRSF2, also influence
APA shifts observed in erythroid differentiation. Taken together, the studies outlined by this proposal will
provide insight into novel regulatory mechanisms of APA utilized during erythropoiesis that functionally alters
key genes. Identification of the molecular regulators of this process, some of which are already implicated in
disease, may suggest novel therapeutic avenues.
Public Health Relevance Statement
Project Narrative
Alternative polyadenylation (APA) is pervasive and expands transcriptome diversity by altering the
length/identity of 3’ untranslated regions (3’UTRs) to alter mRNA stability, localization, and translation.
However, how APA contributes to erythropoiesis remains to be characterized. This project will identify the
patterns of APA during erythropoiesis, the functional consequences of this regulation in key genes, and the
molecular mechanisms that drive it in normal human health and disease.
No Sub Projects information available for 5F31HL162546-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5F31HL162546-02
Patents
No Patents information available for 5F31HL162546-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5F31HL162546-02
Clinical Studies
No Clinical Studies information available for 5F31HL162546-02
News and More
Related News Releases
No news release information available for 5F31HL162546-02
History
No Historical information available for 5F31HL162546-02
Similar Projects
No Similar Projects information available for 5F31HL162546-02